Letrozole Api - Cas No: 112809-51-5, Molecular Formula: C17h11n5, Molecular Weight: 285.30 G/mol | Aromatase Inhibitor For Breast Cancer Treatment, Anti-estrogenic Properties, Excellent Client Approval

Niksan Pharmaceutical is the worlda s top most pharmaceutical company who manufacture, supplies and exports of Letrozole among the all the pharmaceutical companies. We provide best Letrozole API and finished formulations to our customers as well as our group companies. Our product Letrozole is esteemed and praised by clients and also by other companies.
Niksan Pharmaceutical is the largest manufacturer, trader and supplier of Letrozole in all-over Ankleshwar, Gujarat, India.
Niksan Pharmaceutical manufacture and supply the Letrozole product to the Indian states like Maharashtra, Goa, Sikkim, Assam, Punjab, Delhi, Bihar, Karnataka, Meghalaya, Tamilnadu, Kerala, Gujarat, Haryana, Rajasthan, Madhya Pradesh, Uttar Pradesh, Rajasthan, Karnataka, and other states.
Niksan Pharmaceuticals are manufacturing and exporting large quantity of Letrozole in all over the globe for many years in countries like Kenya, Nigeria, Canada, Pakistan, Iraq, New Zealand, Sri Lanka, United States, Australia, United Kingdom, Tanzania, Ireland, Singapore, India, Ghana, Bangladesh, United Arab Emirates, Egypt, South Africa, Puerto Rico, Lebanon, Philippines, Kuwait, Sweden, Israel, Hong Kong, Saudi Arabia, Finland, Morocco, Malaysia, France, Norway, Greece, Iran, Taiwan, Belgium, Switzerland, Portugal, Thailand, South Korea, Romania, Denmark, Hungary, Colombia, Netherlands, Poland, Indonesia, Peru, Mexico, Vietnam , Argentina, Spain, Germany, Brazil, Turkey, Italy, Japan and many other countries.
Letrozole belongs to aromatase inhibitors class of medicine. Letrozole works by stopping the growth of breast cancer cell which needs estrogen to grow. Letrozole inhibits the estrogen level in body.

SYNONYSMS: Letrozole, Letrozol

IUPAC NAME: 4-[(4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl]benzonitrile

CAS NO: 112809-51-5

FORMULA: C17H11N5

MOLECULAR MASS: 285.30 g/mol

STORAGE CONDITIONS: Store the medicine in room temperature and dry place. Place the medication away from direct heat and light. Do not keep medicine in bathroom or humid place. Keep away from children and pets.

HOW TO USE:Take the medicine orally once a day with or without food.Take medicine with milk or food if you feel stomach upset.Take medication regularly to get most benefits of it.

HOW LETROZOLE WORKS: Letrozole blocks the active site of electron transfer chain of CYP19A1.By this Letrozole inhibits the conversion of estrogen form androgen. By this Letrozole stops the growth of cancer cells which needs estrogen to grow.

PHARMACOKINETICS: Letrozole absorbed rapidly in body after oral administration. Letrozole takes 8.10hpurs to reach peak plasma concentration.The bioavaibility of Letrozole is 99.9%.Almost 60% of medicine binds with the plasma proteins.The half-life of this medicine is 42hours.Almost 90% of Letrozole eliminated through urine.

SIDE EFFECTS OF LETROZOLE: The common side effects of Letrozole are headache, nausea, vomiting, dizziness, sweating, tiredness, joint and muscle pain.Tell your doctor if you see side effects like hot flushes, hair loss, bone fracture, swelling of arms or feet, blurred vision, dark urine.Seek immediate medical attention if you see side effects like blood in cough, shortness of breath, arm or leg pain, stomach pain, dizziness, fainting, hair loss, vision change and sudden headache.

PRECAUTIONS:Tell your doctor if you have allergic reaction to the Letrozole medicine.
Tell your doctor if you have history like heart disorder, liver problem, high BP, strokes, blood clot problems.This drug makes you dizzy and because blurred vision so kindly avoid driving, exercise, and operating machineries.Do not consume alcohol or marijuana while taking the medicine.

CDSCO APPROVAL:Lapatinib Ditosylate Tablets 250mg (addl. Indication) approved by CDSCO in India in 10.05.2010
Letrozole 2.5mg tablet (additional indication) approved by CDSCO in India in28.12.2004
Letrozoleapproved by CDSCO in India in 11.02.2002
Palbociclib Capsules 75mg/100mg/125 mg approved by CDSCO in India in11.08.2016
Letrozole tabs approved by CDSCO in India in12.03.1998
Letrozole 2.5mg tablet (for additional indication)approved by CDSCO in India in 10.04.2007

FORMULATIONS AVAILABLE IN MARKET:
Letrozole 5mg tablets
Letrozole 2.5 mg tablets

Note: Product protected by valid patents are not offered for sale in countries where such patents are still valid and its liability is at Buyers Risk

REFERENCES:

www.webmd.com
https://pubchem.ncbi.nlm.nih.gov
https://go.drugbank.com
https://cdscoonline.gov.in
https://www.wikipedia.org/
https://www.drugs.com
https://www.zaubacorp.com
https://www.practo.com/consult